Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Can B Corp CANB

Can B Corp. is a health and wellness company. The Company is engaged in developing, manufacturing, and selling products containing cannabinoids derived from hemp biomass and the licensing of durable medical devices. Its products include oils, creams, moisturizers, isolates, gel caps, spa products, and concentrates and lifestyle products. It develops its own line of proprietary products, as well as seeks synergistic value through acquisitions in the hemp industry. Its Duramed Division provides a sam Pro 2.0 medical device to patients through a doctor program whereby the physician evaluates the patients' needs for medical necessity, and if determined that the device use would be beneficial, writes a prescription for the patient, who signs a rental form, for a 35-day cycle for the unit, that is submitted to Duramed who bills the appropriate insurance company. The Company is also focuses on protecting and commercializing the cannabis patents covering liquid formulations of cannabis.


OTCQB:CANB - Post by User

<< Previous
Bullboard Posts
Next >>
Post by AveragePennyon Nov 05, 2021 12:21pm
133 Views
Post# 34092565

Can B Corp. Reports 316% Revenue Growth to a Quarterly Rev

Can B Corp. Reports 316% Revenue Growth to a Quarterly Rev

Key Financial Highlights during Q3 2021

  • Revenue increased 316% in 3rd quarter 2021 to $1.9 million compared to Q3 2020- (a trend expected to continue into subsequent quarters into 2023
  • Gross profit increased 261% to $1.4 million compared to Q3 2020
  • Total assets increased to 14.2 million
  • Total stockholders' equity increased to $5.7 million

Key Business Highlights during Q3 2021

  • Provided acquisition opportunities to produce 13,000 liters of Delta-8 and other isomers with potential $10 million revenue
  • Secured lease for 300,000 square foot facility in McMinnville, Tennessee
  • Closed acquisition of assets from TWS Pharma in Colorado to significantly expand capabilities in converting hemp biomass to isolate used in our CBD and isomer product lines
  • Closed acquisition of assets from Music City Botanicals to strengthen its vertical processing capabilities
  • Partnered with group of professional Hollywood stuntmen and world champion action sports athletes for CBD products.
  • Company reassessing potential of NASDAQ up-listing
<< Previous
Bullboard Posts
Next >>